We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phytopharm | LSE:PYM | London | Ordinary Share | GB00BCLY7L40 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
TIDMIXI
RNS Number : 6061C
IXICO plc
19 October 2015
IXICO plc
Pre-Close Trading Update
19 October 2015, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2015.
The Company is pleased to report revenues for the year at GBP3.1 million and other income at GBP1.0 million, in line with market expectations, giving combined total income of GBP4.1 million for the year. This compares to GBP4.3 million of total income (GBP3.4 million of revenue and GBP0.9 million of other income) for the 16 month period to 30 September 2014. Revenues in the year were achieved in the clinical trials business, including new contracts in Huntington's Disease, together with initial revenues from the Company's proprietary digital healthcare platform.
Operating expenses have been tightly controlled which has contributed towards a net cash figure at 30 September 2015 of GBP1.92 million which is ahead of market expectations and reflects a modest reduction from the net cash figure of GBP1.95 million at 31 March 2015.
Post the year end, the Company was pleased to announce a strategic collaboration with a leading pharmaceutical company to develop and pilot an adapted version of Assessa(R) for the clinical management of multiple sclerosis. This collaboration is expected to make a material contribution to the Company's revenues in the next 12-18 months which, together with the Phase II global clinical study in neurodegenerative disease announced in August 2015, underpins the board's confidence in meeting current market expectations.
The Company anticipates that its preliminary results to 30 September 2015 will be announced in December 2015.
Enquiries:
IXICO plc +44 20 3763 7499 Derek Hill, CEO Susan Lowther, CFO Charles Spicer, VP Corporate Development Peel Hunt LLP (Nominated Adviser and Broker) +44 20 7418 8900 James Steel Oliver Jackson Daniel Stewart & Company (Joint Broker) +44 207 776 6550 Martin Lampshire David Coffman FTI Consulting Limited (Investor Relations) +44 20 3727 1000 Simon Conway Mo Noonan Matthew Moss
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTFFAFWAFISESS
(END) Dow Jones Newswires
October 19, 2015 02:00 ET (06:00 GMT)
1 Year Phytopharm Chart |
1 Month Phytopharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
